Methylated @entity938 and @entity2529 genes predict prognosis and response to chemotherapy in XXXX .

@entity2529 @entity1 @entity5 @entity938 @entity3 @entity356 @entity1487
@entity356 is the second most common cause of @entity5 deaths worldwide. The identification of molecular genetic parameters that are associated with response to chemotherapy and prognosis is of utmost interest. We examined methylation of the apoptosis-related genes, @entity938 and @entity2529 , in 81 primary @entity356 using methylation-specific PCR and compared their methylation status with clinicopathological findings. Aberrant methylation of @entity938 and @entity2529 genes was detected in 26 (32.1%) @entity5 and in 18 (22.2%) @entity5 , respectively. The overall survival of @entity1 with both methylated genes was significantly shorter compared with those with only one methylated gene or no methylated genes (p = 0.0003). Neither gene methylation had any relation to other clinicopathological findings. Next, we examined 43 @entity1 treated by @entity1487 -based chemotherapy, who had distant @entity3 or recurrence after radical resection, to determine the relation between chemosensitivity and methylation. The response rate was lower in @entity1 with either methylation than without ( @entity938 : 22.2% vs. 48.0%; @entity2529 : 21.4% vs. 44.8%). Overall survival tended to be shorter in the @entity1 with both methylations compared with either or no methylations (p = 0.0806). The time to progression of @entity1 with methylation of @entity938 or @entity2529 was significantly shorter than @entity1 without methylation ( @entity938 : p = 0.0123; @entity2529 : p = 0.0464). Furthermore, the time to progression of @entity1 with both methylated genes was significantly shorter than @entity1 with one methylation or no methylation (p = 0.0082). In conclusion, @entity938 and @entity2529 methylation might predict the prognosis and response to chemotherapy in @entity356 .
